Pharsight

Airsupra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415009 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(5 years from now)

Airsupra is owned by Astrazeneca.

Airsupra contains Albuterol Sulfate; Budesonide.

Airsupra has a total of 1 drug patent out of which 0 drug patents have expired.

Airsupra was authorised for market use on 10 January, 2023.

Airsupra is available in aerosol, metered;inhalation dosage forms.

Airsupra can be used as as-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older.

The generics of Airsupra are possible to be released after 28 May, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 10, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ALBUTEROL SULFATE; BUDESONIDE ingredient

Market Authorisation Date: 10 January, 2023

Treatment: As-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

AIRSUPRA family patents

Family Patents